The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis [PDF]
Arthritis &Rheumatology, Volume 78, Issue 4, Page 970-975, April 2026.Objective Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)–AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim +4 more
wiley +2 more sources
Mast Cell‐Derived CXCL4: A Key Mediator of Ferroptosis and Cardiac Damage in Septic Cardiomyopathy [PDF]
Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.ABSTRACT Background Septic cardiomyopathy (SCM) is a common and life‐threatening complication of severe sepsis, with high mortality due to unclear underlying mechanisms. CXCL4, a key pro‐inflammatory factor, is implicated in various heart diseases, while ferroptosis (iron and lipid hydrogen peroxide‐dependent regulated cell death) plays a crucial role ...
Jing Wei +3 more
wiley +2 more sources
Frontiers in Oncology, 2022 The term ‘magic bullet’ is a scientific concept proposed by the German Nobel laureate Paul Ehrlich in 1907, describing a medicine that could specifically and efficiently target a disease without harming the body. Oncologists have been looking for a magic
Haowen Jiang +5 more
doaj +3 more sources
Nanoengineered Niclosamide as a Microenvironment Modulator for Spinal Cord Regeneration: A Hypothetical Roadmap Toward Brain/Head Transplant Feasibility [PDF]
WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 1, January/February 2026.Nanoengineered niclosamide reprograms the inhibitory spinal lesion microenvironment by modulating fibrosis, inflammation, and ECM remodeling. This perspective outlines a hypothetical roadmap where microenvironment engineering enables meaningful spinal cord reconnection, informing future feasibility of brain or head transplantation.
N. Sanoj Rejinold +2 more
wiley +2 more sources
Electro‐Stimulated Graphene‐Polymer Nanocomposites Enable Wearable Patches With Feedback‐Controlled Drug Release [PDF]
Advanced Healthcare Materials, Volume 15, Issue 15, 17 April 2026.xx xx. ABSTRACT Stimuli‐responsive nanomaterials capable of spatiotemporal control over drug release are of nanocomposite patch (“e‐Medi‐Patch”) engineered from biodegradable polycaprolactone (PCL), graphene nanoplatelets, and a redox‐active therapeutic, niclosamide. The hierarchical composite integrates π‐π interactions between aromatic drug molecules
Santosh K. Misra +7 more
wiley +2 more sources
Chronic Exposure to Niclosamide Disrupts Structure and Metabolism of Digestive Glands and Foot in Cipangopaludina cathayensis [PDF]
BiologyNiclosamide has been the primary molluscicide for schistosomiasis control for over 50 years, but its chronic effects on inter-organ interactions in non-target mollusks remain poorly understood.
Yanan Zhang +6 more
doaj +2 more sources
How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid‐19 [PDF]
Clinical and Translational Science, Volume 19, Issue 2, February 2026.Pharmacological pitfalls and challenges in drug repurposing for emerging pathogens: lessons from COVID‐19. ABSTRACT The Covid‐19 pandemic highlighted the urgent need for effective therapies against emerging pathogens. Drug repurposing, defined as the use of existing medications for new therapeutic purposes, was extensively pursued for SARS‐CoV‐2 but ...
Inès Ben Ghezala +5 more
wiley +2 more sources
Niclosamide Is Active In Vitro against Mycetoma Pathogens [PDF]
Molecules, 2021 Redox-active drugs are the mainstay of parasite chemotherapy. To assess their repurposing potential for eumycetoma, we have tested a set of nitroheterocycles and peroxides in vitro against two isolates of Madurella mycetomatis, the main causative agent ...
Abdelhalim B. Mahmoud +5 more
doaj +5 more sources
Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics [PDF]
Advanced Healthcare MaterialsAbstractNiclosamide, initially developed as an anthelmintic, has recently emerged as a potential antiviral, showing efficacy against diverse viral threats, including Mpox. As the global health landscape faces recurrent Mpox outbreaks, repurposing niclosamide through advanced material strategies offers promising therapeutic avenues.
N. Sanoj Rejinold +2 more
openaire +3 more sources
Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy.
PLoS ONE, 2021 Skeletal muscle atrophy is a feature of aging (termed sarcopenia) and various diseases, such as cancer and kidney failure. Effective drug treatment options for muscle atrophy are lacking.
Hyun-Jun Kim +5 more
doaj +1 more source